Free Trial

BrainsWay Q3 2024 Earnings Report

BrainsWay logo
$9.67 -0.10 (-1.02%)
As of 04:00 PM Eastern

BrainsWay EPS Results

Actual EPS
$0.04
Consensus EPS
$0.01
Beat/Miss
Beat by +$0.03
One Year Ago EPS
-$0.01

BrainsWay Revenue Results

Actual Revenue
$10.50 million
Expected Revenue
$10.07 million
Beat/Miss
Beat by +$430.00 thousand
YoY Revenue Growth
N/A

BrainsWay Announcement Details

Quarter
Q3 2024
Time
Before Market Opens
Remove Ads

BrainsWay Earnings Headlines

HC Wainwright Brokers Lower Earnings Estimates for BrainsWay
Equities Analysts Issue Forecasts for BrainsWay Q1 Earnings
This Crypto Is Set to Explode in February
Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new blockchain development…
Q1 Earnings Forecast for BrainsWay Issued By Northland Capmk
Brainsway sees FY25 revenue $49M-$51M, consensus $47.12M
Brainsway reports Q4 EPS 4c vs. 0c last year
See More BrainsWay Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like BrainsWay? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BrainsWay and other key companies, straight to your email.

About BrainsWay

BrainsWay (NASDAQ:BWAY) develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company serves doctors, hospitals, and medical centers in the field of psychiatry. BrainsWay Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.

View BrainsWay Profile

More Earnings Resources from MarketBeat